Yomiuri: Fujirebio Submits Blood Test Kit for Early Alzheimer's Detection for Approval to Japan Health Ministry

Dow Jones

11/26

By Nozomi Suzuki / Yomiuri Shimbun Staff Writer

Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis.

Alzheimer's disease is thought to occur when abnormal proteins called "amyloid beta" and "tau" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company.

Currently, the procedures for diagnosis include expensive imaging tests like "amyloid PET" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible.

----

This article is from The Yomiuri Shimbun. Neither Dow Jones Newswires, MarketWatch, Barron's nor The Wall Street Journal were involved in the creation of this content.

YDN-M0000160789-1

(END) Dow Jones Newswires

November 26, 2025 02:36 ET (07:36 GMT)

Copyright (c) 2025 The Yomiuri Shimbun

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2586239944"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586239944\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586239944?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 15:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586239944","market":"nz","top_or_hot":-1,"title":"Yomiuri: Fujirebio Submits Blood Test Kit for Early Alzheimer's Detection for Approval to Japan Health Ministry","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nozomi Suzuki / Yomiuri Shimbun Staff Writer \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis. \n</p>\n<p>\n  Alzheimer's disease is thought to occur when abnormal proteins called \"amyloid beta\" and \"tau\" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company. \n</p>\n<p>\n  Currently, the procedures for diagnosis include expensive imaging tests like \"amyloid PET\" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible. \n</p>\n<p>\n    ---- \n</p>\n<p>\n  This article is from The Yomiuri Shimbun. Neither Dow Jones Newswires, MarketWatch, Barron's nor The Wall Street Journal were involved in the creation of this content. \n</p>\n<p>\n  YDN-M0000160789-1 \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 26, 2025 02:36 ET (07:36 GMT)\n</p>\n<p>\n  Copyright (c) 2025 The Yomiuri Shimbun\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yomiuri: Fujirebio Submits Blood Test Kit for Early Alzheimer's Detection for Approval to Japan Health Ministry</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYomiuri: Fujirebio Submits Blood Test Kit for Early Alzheimer's Detection for Approval to Japan Health Ministry\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-11-26 15:36</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nozomi Suzuki / Yomiuri Shimbun Staff Writer \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis. \n</p>\n<p>\n  Alzheimer's disease is thought to occur when abnormal proteins called \"amyloid beta\" and \"tau\" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company. \n</p>\n<p>\n  Currently, the procedures for diagnosis include expensive imaging tests like \"amyloid PET\" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible. \n</p>\n<p>\n    ---- \n</p>\n<p>\n  This article is from The Yomiuri Shimbun. Neither Dow Jones Newswires, MarketWatch, Barron's nor The Wall Street Journal were involved in the creation of this content. \n</p>\n<p>\n  YDN-M0000160789-1 \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 26, 2025 02:36 ET (07:36 GMT)\n</p>\n<p>\n  Copyright (c) 2025 The Yomiuri Shimbun\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6031","symbol_name":"特種化學制品","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2586239944","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586239944","pubTimestamp":1764142560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis.Alzheimer's disease is thought to occur when abnormal proteins called \"amyloid beta\" and \"tau\" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company.Currently, the procedures for diagnosis include expensive imaging tests like \"amyloid PET\" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible.This article is from The Yomiuri Shimbun. Neither Dow Jones Newswire","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6031":"特种化学制品","SG9999001069.SGD":"UOB UNITED ASIA PACIFIC GROWTH (SGD) ACC","BK6102":"燃气公用事业","SG9999003461.SGD":"United Asia Pacific Infrastructure SGD","A7RU.SI":"吉宝基础设施信托","BK6501":"化工股","SG9999004360.SGD":"Nikko AM Shenton Thrift Fund SGD","SG9999002950.SGD":"United Asian Growth Opportunities SGD","SG9999003826.SGD":"日兴资管新加坡股息基金 SGD"},"translate_title":"读卖新闻：Fujirebio向日本厚生省提交用于早期阿尔茨海默病检测的血液检测试剂盒以供批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A7RU.SI":1.5},"content_text":"By Nozomi Suzuki / Yomiuri Shimbun Staff Writer \n\n\n \n\n\n  Japanese testing reagent maker Fujirebio Inc. announced on Tuesday that it has applied to the Japanese Health, Labor and Welfare Ministry for approval to manufacture and sell a blood test kit to assist in diagnosing Alzheimer's disease. The kit is expected to reduce the burden on patients compared to conventional tests, and lead to earlier diagnosis. \n\n\n  Alzheimer's disease is thought to occur when abnormal proteins called \"amyloid beta\" and \"tau\" accumulate in the brain, damaging nerve cells and leading to cognitive decline. The test kit measures the concentration of these proteins in plasma, according to the company. \n\n\n  Currently, the procedures for diagnosis include expensive imaging tests like \"amyloid PET\" scans and invasive lumbar puncture procedures to test cerebrospinal fluid. If approved, Fujirebio's test would only require a blood draw, thus reducing the burden on patients and believed to make testing more accessible. \n\n\n    ---- \n\n\n  This article is from The Yomiuri Shimbun. Neither Dow Jones Newswires, MarketWatch, Barron's nor The Wall Street Journal were involved in the creation of this content. \n\n\n  YDN-M0000160789-1 \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2025 02:36 ET (07:36 GMT)\n\n\n  Copyright (c) 2025 The Yomiuri Shimbun","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}